

Retrophin

Retrophin, Inc.
Investor Relations Department
12255 El Camino Real Suite 250
San Diego, CA 92130
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: RTRX

| | |
|---------------|----------------------------|
| Last Trade: | 16.51 |
| Trade Time: | 4:00 PM ET May 26, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 15.88 - 24.57 |
| Volume | N/A |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Retrophin, Inc. (NASDAQ: RTRX) is a publicly-traded, San Diego-based biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options. The Company is currently focused on several catastrophic diseases affecting children, including Focal Segmental Glomerulosclerosis (FSGS), Pantothenate Kinase-Associated Neurodegeneration (PKAN), and others.

Retrophin is currently enrolling patients in a potentially pivotal Phase ... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 25, 2017
[Retrophin Announces Presentations for Late-Stage Clinical Development Programs at Upcoming Medical Congresses](#)
- May 23, 2017
[Retrophin to Present at the Jefferies 2017 Global Healthcare Conference](#)
- May 4, 2017
[Retrophin Reports First Quarter 2017 Financial Results](#)
- Apr 20, 2017
[Retrophin to Report First Quarter 2017 Financial Results](#)
- Apr 12, 2017
[Retrophin Appoints Ron Squarer to Board of Directors](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 1, 2017
[Annual Report \(10-K\)](#)
- Apr 14, 2017
[Proxy Statement \(DEF 14A\)](#)
- May 5, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 4, 2016
[Quarterly Report \(10-Q\)](#)
- Aug 5, 2016
[Quarterly Report \(10-Q\)](#)